Skip to main content
OpenTrials
Completed

NCT Number: NCT03485131

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations

This is a 4 week therapeutic pilot study with a 4 week follow-up period involving inpatients with treatment resistant DSM-IV schizophrenia or schizoaffective disorder diagnosis. Each eligible subject will receive either 20 minutes of active tDCS (transcranial direct-current stimulation) or sham stimulation twice a day on 5 consecutive weekdays for 4 weeks with a 4 week follow-up period.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Manhattan Psychiatric Center

New York, 10035, United States

About this study

The aim in this study is to conduct a pilot study on the efficacy of tDCS by assessing its efficacy in treatment refractory auditory verbal hallucinations in inpatients with chronic schizophrenia. Based on and expanding the findings by Brunelin et al. the hypothesis is that tDCS treatment with the cathode on the left temporal-parietal junction and the anode on the left dorsolateral prefrontal cortex can reduce the severity of auditory verbal hallucinations in patients with treatment refractory schizophrenia. The impact of tDCS on other schizophrenia symptoms in secondary exploratory outcome analyses together with the examination of the durability of an ameliorating effect will also be investigated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inpatient adults (age 18-65 years) who meet diagnostic criteria for schizophrenia or schizoaffective disorder (using the Structured Clinical Interview for DSM)
  • Auditory hallucinations without remission over 5 years (remission is defined as a period of 4 weeks without hallucinations) as documented in the patients' medical record
  • Failure to respond to two previous adequate antipsychotic trials with adequate duration and adequate dosage
  • Screening PANSS total rating of > 70
  • PANSS hallucinatory behavior item > 4
  • Capacity and willingness to sign informed consent
  • On a stable antipsychotic regimen 4 weeks prior to screening and for the duration of the trial
  • Normal hearing
  • If female and not infertile, must agree to use one of the following forms of contraception for the duration of study participation: systemic hormonal treatment, an interuterine device (IUD) which was implanted at least 2 months prior to screening, or "double-barrier" contraception
  • Willing to wear the tDCS device.

Exclusion criteria

  • Prior history of seizure, other than that induced by Electro Convulsive Therapy
  • Family history of seizures
  • Significant unstable medical condition
  • Pregnancy or women of childbearing capacity not using a medically accepted form of contraception when engaged in sexual intercourse
  • Inability to provide informed consent
  • Actively suicidal and or showing violent behavior
  • Significant organic brain pathology by history and neurological examination, inclusive of history of head trauma, loss of consciousness for more than 5 minutes; intracranial metal implants, known structural brain lesion, devices that may be affected by transcranial Direct Current Stimulation (tDCS) (pacemaker, medication pump, cochlear implant, implanted brain stimulator)
  • Active substance abuse
  • Increased intracranial pressure, unstable cardiovascular disease, sleep apnea
  • Individuals with a clinically defined neurological disorder
  • Frequent and persistent migraines
  • History of adverse reaction to neurostimulation or open skin wounds that would preclude safe placement of tDCS electrodes
  • Current use of medications known to lower seizure threshold (serotonergic or tricyclic antidepressants)
  • If pregnant or breast feeding at the time of screening

Treatment and study plan

Transcranial direct-current stimulation (tDCS)

Device

Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks

Other names: Active Transcranial direct-current stimulation (tDCS)'

PLACEBO

Device

Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period

Other names: Sham Transcranial direct-current stimulation (tDCS)

Primary outcomes

  1. Reduction on the severity of auditory verbal hallucinations

    Time frame: 8 weeks

    Reduction of Auditory Hallucinations Rating Scale (AHRS (12) items)

Secondary outcomes

  1. Impact of tDCS on other schizophrenia symptoms

    Time frame: 8 weeks

    Reduction of scores in Positive and Negative Symptom Scale

  2. Impact of tDCS on Clinical Global Impression

    Time frame: 8 weeks

    Global Severity of Illness measure

  3. Impact of tDCS on MATRICS

    Time frame: 8 weeks

    MATRICS: Comprehensive assessment of cognitive functions

Sponsors and collaborators

Lead sponsor

Manhattan Psychiatric Center

Other

Registry information

Official study title

Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations: A Pilot Study

Acronym: tDCS

Important dates

Study start
2014
Primary completion
2017
Study completion
2018
First posted
Apr 2, 2018
Registry last updated
Apr 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.